SecBot SecBot
6-K ·Filed Sep 1, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001654954-26-007990
Actionable Insight ▲ Bullish

The EU approval is a major commercial catalyst for Enhertu, expanding its label to the lucrative first-line metastatic setting and setting a new standard of care. Traders should monitor upcoming quarterly sales reports for Enhertu in the EU for evidence of revenue acceleration. The $100M milestone is a modest cost relative to the potential revenue upside. The director appointment is routine and has no trading implications.

DirectionBullish
Confidencehigh
Horizonweeks

Drug in focus

AZN drug pipeline →

trastuzumab deruxtecan

● Neutral Named in this 6-K
Impact
Phase
Approved
Time to market
Already approved and commercialized (since 2019 for initial indication)
Next catalyst
None dated

What to watchFor investors in AZN, Enhertu is a mature commercial asset driving growth, not a binary catalyst. The next watchpoint is the readout of DESTINY-Gastric04 (Phase 3 in HER2+ gastric cancer, estimated primary completion Aug 2026). For VIVS/VivoSim Labs, the drug is not theirs, they merely tested it on a safety platform, so any trading thesis tied to trastuzumab deruxtecan should not involve VIVS stock.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$162.22
T+0 close · Sep 1, 2026 · via day close
Latest settled
−0.46%
T+20 · $161.47 · next T+60 in 9d
Vs SPY
−0.57%
α at T+20
Latest observation
+14.90%
T+52 · FF3 residual α
  1. T+0 · Sep 1 $162.22entry
  2. T+1 · 3mo ago −0.58%α −1.02% · $161.28
  3. T+5 · 2mo ago −3.25%α −3.33% · $156.94
  4. T+20 · 7w ago −0.46%α −0.57% · $161.47
  5. T+53 · todayOpen
  6. T+60 · in 9d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab received EU approval for 1st-line treatment of HER2-positive metastatic breast cancer, based on the DESTINY-Breast09 Phase III trial showing a 44% reduction in risk of disease progression or death vs. standard of care (THP). This approval triggers a $100 million milestone payment from AstraZeneca to Daiichi Sankyo. Separately, AstraZeneca appointed Wan Ling Martello as a Non-Executive Director and Audit Committee member, a routine board change with no material financial impact.

Key Facts

  • Enhertu plus pertuzumab approved in the EU for 1st-line treatment of HER2-positive metastatic breast cancer.
  • Approval based on DESTINY-Breast09 Phase III trial showing 44% reduction in risk of disease progression or death (HR 0.56; p<0.00001) vs. THP.
  • Median progression-free survival was 40.7 months with Enhertu combination vs. 26.9 months with THP.
  • A $100 million milestone payment is due from AstraZeneca to Daiichi Sankyo following this EU approval.
  • Wan Ling Martello appointed as Non-Executive Director and Audit Committee member, a routine board appointment.

Financial Impact

A $100 million milestone payment due from AstraZeneca to Daiichi Sankyo for the EU approval. The approval expands Enhertu's addressable market in the EU to the 1st-line setting, representing a significant revenue growth catalyst for the Enhertu franchise.

revenuemilestone payments

Risk Factors

  • Competition from other HER2-directed therapies (e.g., Roche's Perjeta/Herceptin) and potential pricing/reimbursement pressures in EU markets.
  • The $100M milestone payment is a small but real cash outflow.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (AZN), Batch item 10001654954-26-007990
Document: 0001654954-26-007990-index-headers.html0001654954-26-007988
Document: 0001654954-26-007990-index.html0001654954-26-007990
Document: 0001654954-26-007990.txt0001654954-26-007990
6-K Filing (AZN), Batch item 50001654954-26-007988
Document: 0001654954-26-007988-index-headers.html0001654954-26-007990
Document: 0001654954-26-007988-index.html0001654954-26-007990
Document: 0001654954-26-007988.txt0001654954-26-007990

Track record

77 reports on AZN

Performance horizon

19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202611d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Tue (16h 42m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 1, 2026